Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with osteoarthritis of the knee based on the American College of Rheumatology (ACR) criteria and functional capacity class of I- III;~* Patients taking analgesic medications for at least 3 months prior to screening and dissatisfied with their current therapy;~* Patients requiring opioid treatment must be taking daily doses of opioid- based analgesic, equivalent to \<160 mg of oral morphine;~* Baseline score of \>=5 on an 11-point numeric rating scale, calculated as the average pain intensity during the last 3 days prior to randomization.~Exclusion Criteria:~* History of alcohol and/or drug abuse in Investigator's judgment;~* Chronic hepatitis B or C, or HIV, presence of active hepatitis B or C within the past 3 months;~* Life-long history of seizure disorder or epilepsy;~* History of malignancy within past 2 years, with exception of basal cell carcinoma that has been successfully treated;~* Uncontrolled hypertension;~* Patients with severely impaired renal function;~* Patients with moderate to severely impaired hepatic function or with laboratory values reflecting inadequate hepatic function,~* Treatment with neuroleptics, monoamine oxidase inhibitors, serotonin norepinephrine reuptake inhibitors (SNRI), tricyclic antidepressants, anticonvulsants, or anti-parkinsonian drugs, treatment with any other analgesic therapy than investigational medication or rescue medication during the trial.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Matching Placebo (twice daily) (Type: PLACEBO_COMPARATOR): The starting dose of placebo was matched with the active treatment arms taken twice daily for the first 3 days. The dose was then increased to match the active treatments for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days as in the active treatment arms. Dose decreases were allowed without time restrictions.
- Tapentadol ER (100 to 250 mg twice daily) (Type: EXPERIMENTAL): The starting dose was tapentadol ER 50 mg twice daily for 3 days. The dose was then increased to 100 mg tapentadol ER twice daily for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days. Dose decreases were allowed without time restrictions.
- Oxycodone CR (20 to 50 mg twice daily) (Type: ACTIVE_COMPARATOR): The starting dose was oxycodone CR 10 mg twice daily for 3 days. The dose was then increased to 20 mg oxycodone CR twice daily for at least 4 days. Thereafter, during the titration and maintenance phase participants were allowed to increase the dose every 3 days. Dose decreases were allowed without time restrictions.

Based on this trial design, predict the completion outcome and termination type (if applicable).